510(k) clearance has been awarded to artificial intelligence-based tool designed to accelerate respiratory disease diagnosis.
Nines Radiology announced Tuesday it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new lung nodule measurement tool, NinesMeasure™.
Built using artificial intelligence (AI), this tool is designed to facilitate rapid diagnosis of respiratory conditions. Its development is also unique, said company officials.
“To our knowledge, NinesMeasure is the only lung nodule measurement tool cleared by the FDA that was developed by a combined team of radiologists and engineers collaborating every day,” said Michael Kelleher, M.D., Nines Radiology president, noting that radiologists are paired with house engineers for development. “This advanced tool can significantly reduce the amount of time our radiologists spend measuring pulmonary nodules, improving time to diagnosis for patients without rushing our radiologists.”
This marks the Silicon Valley-based company’s second FDA clearance in 10 months, following its AI-based technology that triages mass effect conditions and intracranial hemorrhages.
According to company data, NinesMeasure is designed to help radiologists measure nodules along the long and short axes quickly and with high accuracy. It can also help providers address inter-study consistency throughout a patient’s treatment.
With this clearance, Nines also augmented its product offerings that have led to significant improvements in non-diagnostic workflow and fewer distractions by administrative tasks, the company said. On average, they said, the company’s focus on improving clinical workflow has led to a 40-percent gain in efficiency for radiology customers.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
AI Radiology ROI Calculator Study Projects 451 Percent ROI Over Five Years
March 18th 2024Incorporating an artificial intelligence (AI) platform into the radiology workflow at a stroke management-accredited hospital may lead to projected savings of 78 days in triage time and 41 days in reporting time for radiologists over a five-year period, according to new research.